|
|
|
|
|
4095.0: Tuesday, November 9, 2004: 12:30 PM-2:00 PM | |||
Poster | |||
| |||
| Learning Objectives: See individual abstracts. | |||
| Office-based buprenorphine treatment for opiate dependency: Policy to practice challenges in an urban setting Marilyn Ann DeLuca, PhD, RN, Andrew J. Kolodny, MD | |||
| Buprenorphine-assisted recruitment of opioid-dependent patients into residential treatment: The First Step model at Phoenix House Terry Horton, MD, Eric D. Collins, MD, Katherine Reinke, MS, RN, Edward V. Nunes, MD, Leslie Amass, PhD | |||
| Office-based opioid treatment: New interventions to treat prescription opioid abuse C. Danielle Johnson, MPH, Nicholas Reuter, MPH | |||
| Eighty-four cost outcome analyses in substance abuse prevention and acute harm reduction Ted R. Miller, PhD, Delia Hendrie | |||
| Summer time and the buyin's easy: Lessons learned from the Youth Health Advisory Council survey on youth access to ATOD in Marin County Margaret Libby, MSW, Maureen Sedonaen | |||
| Effective alternatives: Utilizing social marketing strategies to implement a prenatal substance abuse referral project in medical offices Augustine McDaniel-Smith, MBA, Tamarra C. Jones, MPH, CHES, Rachel Gonzales, MPH, Amy S. Myerson, MA | |||
| Community participatory activities (CPA) and ATOD use among adolescents Mian B. Hossain, MSC, MHS, PhD, Joy P. Nanda, DSc, MS, MHS, Ava Joubert-Curtis, MD, Ivana Amaris Vaughn, MPH(c), Kia Tolson, MPH, J. Prince James, MPH, Jamaal A. Russell, MPH, MT, Sharrone Bryant, MA, MS | |||
| Attitudes toward ibogaine among clients and counselors in drug treatment programs Marilyn C. Daley, PhD, Dennis McCarty, PhD, Cindy Parks Thomas, PA, PhD, Traci Rieckmann, PhD | |||
| Twelve month outcomes of fully, partially and minimally integrated approaches to treating persons with co-occurring mental health and substance abuse disorders Roy M. Gabriel, PhD, Kelly Vander Ley, PhD, Jennifer Lembach, BA | |||
| Modelling of responses in risk behaviour indicators subject to measurement errors Perpetual Chikobvu, PhD, Carl Lombard, PhD, Alan J. Flisher, PhD, Loraine Townsend, MA, Martie Muller, MSc, Gary King, PhD | |||
| See individual abstracts for presenting author's disclosure statement and author's information. | |||
| Organized by: | Alcohol, Tobacco, and Other Drugs | ||